MediciNova (MNOV) Stock Price, News & Analysis

Company Overview

MediciNova, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel small-molecule therapeutics for neurodegenerative, inflammatory, fibrotic and oncological diseases. Founded in the late 1990s, the company advances its proprietary compounds through clinical trials and strategic partnerships, with a goal of addressing areas of high unmet medical need. MediciNova is headquartered in San Diego, California, and maintains a presence in Tokyo to support collaborations and regulatory interactions in Asian markets.

The company’s leading clinical asset, MN-166 (ibudilast), is an anti-inflammatory and neuroprotective agent originally approved in Japan for asthma and post-stroke dizziness. MediciNova is evaluating ibudilast in multiple late-stage and exploratory studies, including progressive multiple sclerosis, amyotrophic lateral sclerosis (ALS) and substance use disorders such as opioid and alcohol dependence. Ibudilast’s mechanism of action involves modulation of glial cell activity in the central nervous system, aiming to slow neurodegeneration and reduce inflammation.

Another key compound, MN-001 (tipelukast), is a leukotriene receptor antagonist in development for idiopathic pulmonary fibrosis (IPF), nonalcoholic steatohepatitis (NASH) and diabetic nephropathy. MN-001 has completed Phase II trials in IPF patients and is being positioned as a potential treatment for a range of progressive fibrotic conditions. MediciNova also maintains a preclinical respiratory portfolio, including β1-adrenergic agonists aimed at acute lung injury and chronic obstructive pulmonary disease (COPD).

MediciNova leverages partnerships with pharmaceutical companies in Japan and globally to support late-stage trials and potential commercialization. The company’s multidisciplinary leadership team brings together expertise in clinical development, regulatory affairs and global business development to advance its pipeline. Through a combination of in-house research and strategic alliances, MediciNova seeks to deliver new therapies across multiple therapeutic areas with significant market opportunities.

Key Stats

• Today's Range: $1.36 to $1.40
• 50-Day Range: $1.36 to $1.56
• 52-Week Range: $1.17 to $1.96
• Volume: 34,079 shs
• Average Volume: 55,278 shs
• Market Capitalization: $67.43 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.50
• Consensus Rating: Moderate Buy

MediciNova Stock Analysis - MarketRank™

MediciNova scored higher than 45% of companies evaluated by MarketBeat, and ranked 597th out of 867 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

MediciNova has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 2 strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

MediciNova has a consensus price target of $7.50, representing about 447.4% upside from its current price of $1.37.

Amount of Analyst Coverage

MediciNova has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for MediciNova are expected to decrease in the coming year, from ($0.26) to ($0.43) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of MediciNova is -5.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of MediciNova is -5.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

MediciNova has a P/B Ratio of 1.71. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

0.41% of the float of MediciNova has been sold short.

Short Interest Ratio / Days to Cover

MediciNova has a short interest ratio ("days to cover") of 8.42.

Change versus previous month

Short interest in MediciNova has recently increased by 2.56%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

MediciNova does not currently pay a dividend.

Dividend Growth

MediciNova does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for MediciNova this week, compared to 2 articles on an average week.

Search Interest

2 people have searched for MNOV on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.6 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, MediciNova insiders have not sold or bought any company stock.

Percentage Held by Insiders

14.00% of the stock of MediciNova is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

9.90% of the stock of MediciNova is held by institutions.

Company Calendar

• Last Earnings: 5/15/2026
• Today: 5/26/2026
• Next Earnings (Estimated): 8/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MNOV
• CIK: 1226616
• Web: medicinova.com
• Phone: (858) 373-1500
• Fax: 858-404-0048
• Employees: 10
• Year Founded: 2000

Price Target and Rating

• Average Price Target for MediciNova: $7.50
• High Price Target: $10.00
• Low Price Target: $5.00
• Potential Upside/Downside: +447.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.86
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.23)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$12 million
• Net Margins: -1,962.98%
• Pretax Margin: -1,962.14%
• Return on Equity: -27.28%
• Return on Assets: -25.24%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.09
• Quick Ratio: 9.09

Sales & Book Value

• Annual Sales: $410 thousand
• Price / Sales: 164.47
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.80 per share
• Price / Book: 1.71

Miscellaneous

• Outstanding Shares: 49,220,000
• Free Float: 42,330,000
• Market Cap: $67.43 million
• Optionable: Optionable
• Beta: 0.63